Complement System Inhibitor

Cevolisiran sodium, a siRNA, is a complement component 3 (C3) synthesis reducer.

Avacincaptad pegol sodium scrambled negative control is the sequence scrambled negative control of Avacincaptad pegol sodium.

Agazisiran sodium, a siRNA,is a complement factor B synthesis reducer.

3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that exhibits significant anticomplement activity with an IC₅₀ of 89.5 μM.

Tarvicopan is an inhibitor for complement factor D.

Anti-CD88/C5AR1 Antibody (G2_anti-C5aR) is a human monoclonal antibody (mAb) targeting C5AR1.

Cevolisiran sodium scrambled negative control is the sequence scrambled negative control of Cevolisiran sodium.

Dexamethasone-d₅-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.

Cevolisiran, a siRNA, is a complement component 3 (C3) synthesis reducer.

MEDI7814 is a humanized monoclonal antibody inhibitor targeting C5a and C5adesArg. MEDI7814 binds to recombinant human C5a and serum purified human C5a with affinities of 14 pM and 8 pM, respectively. MEDI7814 is acute inflammatory diseases such as sepsis and renal ischemia-reperfusion injury.

Avacopan (Standard) is the analytical standard of Avacopan. This product is intended for research and analytical applications. Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC₅₀ of 0.1 nM.

Bisphenol A bissulfate disodium is a metabolite of Bisphenol A (HY-18260). Bisphenol A bissulfate disodium (compound 7) show complement-inhibiting activity with an IC₅₀ of 247 μM.

Zilucoplan (PEG2) is a Zilucoplan (HY-P3502) derivative, where the linker section replaces PEG24 by PEG2. Zilucoplan is a potent complement component 5 (C5) inhibitor.

Factor B-IN-5 (Example 5 target compound) is a potent complement factor B inhibitor, with an IC₅₀ of 1.2 μM. Factor B-IN-5 can be used for the research of diseases related to inflammation and immunity.

Anti-Mouse C5aR Antibody (20/70) reacts with mouse C5aR. Anti-Mouse C5aR Antibody (20/70) blocks C5aR both in vivo and in vitro. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human GC1q R/C1QBP. Anti-GC1q R/C1QBP Antibody (60.11) can neutralize GC1q R. Anti-GC1q R/C1QBP Antibody (60.11) can be used for the researches of cancer, infection and inflammation, such as MDA231 tumor and S. aureus induced infective endocarditis (IE).

Cyclosporin A-d₃ (Cyclosporine A-d₃) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC₅₀ of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.

Ldalaptican pegol (AON-D21; NOX-D21) is a PEGylated mixed RNA/DNA L-aptamer that specifically binds to complement C5a. Ldalaptican pegol binds to C5a and the C5a moiety on uncleaved C5, thereby blocking C5a signaling. This inhibition suppresses downstream inflammatory responses, immune cell infiltration and chemotaxis, the release of pro-fibrotic factors, and abnormalities in lipid metabolism signaling pathways. Ldalaptican pegol can also alleviate allograft rejection. Ldalaptican pegol can be used in research on inflammatory muscle diseases, Duchenne muscular dystrophy (DMD), diabetes, renal fibrosis, and allograft organ transplant rejection.